Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jignesh P Patel

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Thrombosis Research|November 21, 2021
Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching StudyJohn K Bartoli-Abdou, Jignesh P Patel, Bipin Vadher, et al.
Thrombosis and Haemostasis|October 17, 2023
Factor Xa Inhibitor Plasma Concentrations and Clinical Outcomes in Patients Weighing ≤50 kg-Experience from Four UK CentersVictoria Speed, Rachel Clapham, John Bartoli-Abdou, et al.
BMC Hematology|August 26, 2016
Anticoagulated patient's perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy - study protocol for The Switching Study: a prospective cohort studyVivian Auyeung, Jignesh P Patel, John K Abdou, et al.
Thrombosis Research|January 7, 2018
Exploration of adherence and patient experiences with DOACs one year after switching from vitamin-K antagonists- insights from the switching studyJohn K Bartoli-Abdou, Jignesh P Patel, Jacob Crawshaw, et al.
Clinical Toxicology (Philadelphia, Pa.)|February 10, 2015
Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatranJosée Bouchard, Marc Ghannoum, Amélie Bernier-Jean, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Associations between illness beliefs, medication beliefs, anticoagulation-related quality of life, and INR control: Insights from the Switching StudyJohn K Bartoli-Abdou, Jignesh P Patel, Rosa Xie, et al.
Thrombosis Research|August 24, 2024
Can edoxaban be used at extremes of bodyweight and in patients with a creatinine clearance ≥95 ml/min? - A population pharmacokinetic analysisRachel E Clapham, Victoria Speed, Rosalind Byrne, et al.
British Journal of Clinical Pharmacology|August 27, 2021
Population pharmacokinetics and dose optimisation of colecalciferol in paediatric patients with chronic kidney diseaseMandy Wan, Bruce Green, Arpana Aprameya Iyengar, et al.
Thrombosis Research|November 23, 2020
Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemicRachna Patel, Julia Czuprynska, Lara N Roberts, et al.
Journal of Thrombosis and Haemostasis : JTH|June 9, 2020
Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysisVictoria Speed, Bruce Green, Lara N Roberts, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Thrombosis Research|November 21, 2021
Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching StudyJohn K Bartoli-Abdou, Jignesh P Patel, Bipin Vadher, et al.
Thrombosis and Haemostasis|October 17, 2023
Factor Xa Inhibitor Plasma Concentrations and Clinical Outcomes in Patients Weighing ≤50 kg-Experience from Four UK CentersVictoria Speed, Rachel Clapham, John Bartoli-Abdou, et al.
BMC Hematology|August 26, 2016
Anticoagulated patient's perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy - study protocol for The Switching Study: a prospective cohort studyVivian Auyeung, Jignesh P Patel, John K Abdou, et al.
Thrombosis Research|January 7, 2018
Exploration of adherence and patient experiences with DOACs one year after switching from vitamin-K antagonists- insights from the switching studyJohn K Bartoli-Abdou, Jignesh P Patel, Jacob Crawshaw, et al.
Clinical Toxicology (Philadelphia, Pa.)|February 10, 2015
Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatranJosée Bouchard, Marc Ghannoum, Amélie Bernier-Jean, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Associations between illness beliefs, medication beliefs, anticoagulation-related quality of life, and INR control: Insights from the Switching StudyJohn K Bartoli-Abdou, Jignesh P Patel, Rosa Xie, et al.
Thrombosis Research|August 24, 2024
Can edoxaban be used at extremes of bodyweight and in patients with a creatinine clearance ≥95 ml/min? - A population pharmacokinetic analysisRachel E Clapham, Victoria Speed, Rosalind Byrne, et al.
British Journal of Clinical Pharmacology|August 27, 2021
Population pharmacokinetics and dose optimisation of colecalciferol in paediatric patients with chronic kidney diseaseMandy Wan, Bruce Green, Arpana Aprameya Iyengar, et al.
Thrombosis Research|November 23, 2020
Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemicRachna Patel, Julia Czuprynska, Lara N Roberts, et al.
Journal of Thrombosis and Haemostasis : JTH|June 9, 2020
Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysisVictoria Speed, Bruce Green, Lara N Roberts, et al.
Pageof 7